{"text": "Biomarkers, such as PD-L1 and the tumor mutation burden (TMB), enable better selection of patients who should benefit the most from first-line ICI use.", "denotations": [{"id": "T1", "obj": "gene", "span": {"begin": 20, "end": 25}}, {"id": "T2", "obj": "disease", "span": {"begin": 34, "end": 39}}]}
